Navigation Links
Avista Capital Partners Appoints Hakan Bjorklund as Healthcare Operating Executive
Date:10/6/2011

NEW YORK, Oct. 6, 2011 /PRNewswire/ -- Avista Capital Partners, a leading private equity firm, today announced that it has hired Hakan Bjorklund, the departing Chief Executive Officer of Nycomed, as Healthcare Operating Executive.  Mr. Bjorklund worked closely with Avista on the development of Nycomed during Avista's ownership of the company, which was recently sold to Takeda Pharmaceuticals Company Limited for Euro 9.6 billion.

Under Mr. Bjorklund's leadership, Nycomed was transformed from a predominantly Scandinavian business into a global pharmaceutical company with leading market positions in Europe, Russia/CIS, Brazil and Latin America.  In 2006, Mr. Bjorklund led the integration of Altana Pharmaceutical, a German-based company that Nycomed purchased for Euro 4.2 billion. He was also instrumental in growing Nycomed in emerging markets, most recently through the acquisition of Guangdong Techpool Bio-Pharma Co., Ltd, a fast growing Chinese bio-pharmaceutical company, in 2010.    

Thompson Dean, Co-Managing Partner and Chief Executive Officer of Avista, said, "We are delighted to welcome Hakan to Avista.  One of the top pharmaceutical executives in Europe, he possesses a deep understanding of the global healthcare market.  Having worked closely with him for many years, I know that Hakan will bring extensive strategic, operational and investment expertise to Avista as well as strong relationships throughout the global healthcare sector."    

Newton Aguiar, the partner in charge of Avista's European operations, added, "We are looking forward to working with Hakan on healthcare investments both in Europe and throughout the world.  Hakan built Nycomed into one of the fastest growing global pharmaceutical companies, in part, by expanding its presence in key emerging markets, particularly in Russia/CIS and Latin America.  His experience will be invaluable to the healthcare management teams in Avista's portfolio as they seek to grow their own businesses."    

Mr. Bjorklund said, "This is a very exciting opportunity. Avista is a leading private equity healthcare investor with a long track record of successful investments in the pharmaceutical, medical device, and healthcare services sectors.  As CEO of Nycomed, I was deeply impressed by the sector expertise and supportive ownership philosophy that Avista brings to its investments.  I am looking forward to helping other leading healthcare companies reach their full potential as a member of the Avista team."

Before joining Nycomed, Mr. Bjorklund was Regional Director at Astra (now AstraZeneca) and, earlier, President of Astra Draco.  He is a member of the Board of Directors of Coloplast A/S, Lundbeck A/S, and Atos Medical AB. He was also a director at Danisco A/S until its recent acquisition by Dupont.  He holds a Ph.D. in Neuroscience from Karolinska Institutet in Sweden.

In addition to Nycomed, Avista's portfolio of healthcare companies includes INC Research, a leading clinical research organization; ConvaTec, a global leader in ostomy and wound care; Lantheus, a leader in diagnostic imaging; Navilyst Medical, a manufacturer and distributor of single-use fluid management and venous-access medical devices; BioReliance, a leading contract services provider focused on biological safety testing, toxicology, viral manufacturing, and laboratory animal diagnostic services; and VWR International, a leading global distributor of equipment and consumable supplies to the laboratory sector across all industries.  In addition, during its time at DLJ Merchant Banking Partners, the Avista team was significantly involved in a variety of healthcare investments, including medical device companies such as Accellent and Kinetic Concepts; healthcare services companies such as Focus Diagnostics, Charles River Laboratories, and Fisher Scientific International; and pharmaceutical companies such as Warner Chilcott and Prometheus Laboratories.

About Avista Capital Partners

Avista Capital Partners is a leading private equity firm with offices in New York, Houston, and London. Avista's strategy is to make controlling or influential minority investments in growth-oriented energy, healthcare, media, industrial and consumer businesses. Through its team of seasoned investment professionals and industry experts, Avista seeks to partner with exceptional management teams to invest in and add value to well-positioned businesses. For more information visit www.avistacap.com.  

Contact

Melissa Sheer or James David
Kekst and Company
212-521-4825


'/>"/>
SOURCE Avista Capital Partners
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ARAMARK Agrees to Sell its Galls Business to CI Capital Partners
2. Medical Alarm Concepts Receives Growth Capital Injection and Commitment for Future Funding
3. K-V Pharmaceutical Company to Present at Imperial Capitals 5th Annual Global Opportunities Conference
4. Water Street Healthcare Partners Completes Sale and Recapitalization of CareCentrix
5. Thoratec Presentation at Lazard Capital Markets Circulatory Assist Device Day to be Webcast
6. HeartWare to Present at The Lazard Capital Markets 3rd Annual Circulatory Assist Device Day
7. HealthTech Capital Announces Two New Investments in the Emerging HealthTech Market
8. Main Street Capital Announces New Portfolio Investment
9. MGT Capital Investments, Inc.s Plan of Compliance Accepted by NYSE AMEX, LLC
10. CVS Caremark Corporation Announces Receipt of Requisite Consents, Termination of Replacement Capital Covenant and Expiration of Consent Solicitation Relating to its 6.125% Senior Notes due August 15, 2016 (CUSIP NO. 126650BE9)
11. MGT Capital Investments, Inc. Provides Update on Recent Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... to the Centers for Disease Control and Prevention (CDC), influenza vaccination ... is helping communities across Massachusetts , Connecticut ... flu shots through the end of the month. *Some exclusions ... ... shot is by the end of October, according to the Centers for ...
(Date:10/2/2017)... 2, 2017  AllianceRx Walgreens Prime, the combined central ... and pharmacy benefit manager Prime Therapeutics LLC (Prime), today ... included the unveiling of new signage at its headquarters ... as at a few other company-owned facilities across the ... patients, some of whom will begin to see the ...
(Date:9/28/2017)... , Sept. 28, 2017 Cohen Veterans ... advance the use of wearable and home sensors for ... disorders. Early Signal Foundation, a nonprofit organization focused on ... will provide an affordable analytical system to record and ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 13, 2017 , ... Coveros, a leader in agile coaching ... contract by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile ... of Agile methodologies in a consistent and high value manner across CMS programs. ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the ... “America On The Brink” is the creation of published author, William Nowers. Captain ... As a WWII veteran, he spent thirty years in the Navy. Following his ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and ... apnea using cutting-edge Oventus O2Vent technology. As many as 18 million Americans ... frequent cessation in breathing. Oral appliances can offer significant relief to about 75 ...
(Date:10/12/2017)... ... 12, 2017 , ... The company has developed a suite ... regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been developed ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, ...
(Date:10/12/2017)... ... ... The American College of Medical Informatics (ACMI) will present the 2017 Morris ... of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is taking ... in the field of medical informatics, this prestigious award is presented to an individual ...
Breaking Medicine News(10 mins):